51
|
Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity. CNS Spectr 2014; 19:50-61. [PMID: 24176028 DOI: 10.1017/s1092852913000618] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Obsessive-compulsive disorder (OCD) has been recently drawn apart from anxiety disorder by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) and clustered together with related disorders (eg, hoarding, hair pulling disorder, skin picking), which with it seems to share clinical and neurophysiological similarities. Recent literature has mainly explored brain circuitries (eg, orbitofrontal cortex, striatum), molecular pathways, and genes (eg, Hoxb8, Slitrk5, Sapap3) that represent the new target of the treatments; they also lead the development of new probes and compounds. In the therapeutic field, monotherapy with cognitive behavioral therapy (CBT) or selective serotonin reuptake inhibitors (SSRIs) is recommendable, but combination or augmentation with a dopaminergic or glutamatergic agent is often adopted. A promising therapy for OCD is represented by repetitive transcranial magnetic stimulation (rTMS), which is suitable to treat compulsivity and impulsivity depending on the protocol of stimulation and the brain circuitries targeted.
Collapse
|
52
|
Andreou C, Leicht G, Popescu V, Pogarell O, Mavrogiorgou P, Rujescu D, Giegling I, Zaudig M, Juckel G, Hegerl U, Mulert C. P300 in obsessive-compulsive disorder: source localization and the effects of treatment. J Psychiatr Res 2013; 47:1975-83. [PMID: 24075207 DOI: 10.1016/j.jpsychires.2013.09.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Revised: 08/26/2013] [Accepted: 09/06/2013] [Indexed: 11/16/2022]
Abstract
UNLABELLED Converging evidence suggests that frontostriatal abnormalities underlie OCD symptoms. The event-related potential P300 is generated along a widely distributed network involving several of the areas implicated in OCD. P300 abnormalities reported in patients with OCD suggest increased activity in these areas. The aim of the present study was to investigate this assumption in unmedicated patients with OCD, and to assess the effects of OCD treatment on P300 brain activity patterns. Seventy-one unmedicated patients with a DSM-IV diagnosis of OCD and 71 age- and gender-matched healthy control subjects participated in the study. The P300 was obtained through 32-channel EEG during an auditory oddball paradigm. Forty-three patients underwent a second EEG assessment after treatment with sertraline and behavioural therapy. Low-resolution electromagnetic tomography (LORETA) was used to localize the sources of brain electrical activity. RESULTS Increased P300-related activity was observed predominantly in the left orbitofrontal cortex, but also in left prefrontal, parietal and temporal areas, in patients compared to controls at baseline. After treatment, reduction of left middle frontal cortex hyperactivity was observed in patients. CONCLUSIONS Findings of increased activity in frontoparietal areas in patients are consistent with several previous studies. Importantly, OCD treatment led to reduction of hyperactivity in the left middle frontal cortex, an area associated with context processing and uncertainty that might be important for the emergence of OCD symptoms. Thus, the present study is the first to show an association between P300 abnormalities and activity in brain regions postulated to be involved in the pathophysiology of OCD.
Collapse
Affiliation(s)
- Christina Andreou
- Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
53
|
Montigny C, Castellanos-Ryan N, Whelan R, Banaschewski T, Barker GJ, Büchel C, Gallinat J, Flor H, Mann K, Paillère-Martinot ML, Nees F, Lathrop M, Loth E, Paus T, Pausova Z, Rietschel M, Schumann G, Smolka MN, Struve M, Robbins TW, Garavan H, Conrod PJ. A phenotypic structure and neural correlates of compulsive behaviors in adolescents. PLoS One 2013; 8:e80151. [PMID: 24244633 PMCID: PMC3828212 DOI: 10.1371/journal.pone.0080151] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2013] [Accepted: 09/30/2013] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND A compulsivity spectrum has been hypothesized to exist across Obsessive-Compulsive disorder (OCD), Eating Disorders (ED), substance abuse (SA) and binge-drinking (BD). The objective was to examine the validity of this compulsivity spectrum, and differentiate it from an externalizing behaviors dimension, but also to look at hypothesized personality and neural correlates. METHOD A community-sample of adolescents (N=1938; mean age 14.5 years), and their parents were recruited via high-schools in 8 European study sites. Data on adolescents' psychiatric symptoms, DSM diagnoses (DAWBA) and substance use behaviors (AUDIT and ESPAD) were collected through adolescent- and parent-reported questionnaires and interviews. The phenotypic structure of compulsive behaviors was then tested using structural equation modeling. The model was validated using personality variables (NEO-FFI and TCI), and Voxel-Based Morphometry (VBM) analysis. RESULTS Compulsivity symptoms best fit a higher-order two factor model, with ED and OCD loading onto a compulsivity factor, and BD and SA loading onto an externalizing factor, composed also of ADHD and conduct disorder symptoms. The compulsivity construct correlated with neuroticism (r=0.638; p ≤ 0.001), conscientiousness (r=0.171; p ≤ 0.001), and brain gray matter volume in left and right orbitofrontal cortex, right ventral striatum and right dorsolateral prefrontal cortex. The externalizing factor correlated with extraversion (r=0.201; p ≤ 0.001), novelty-seeking (r=0.451; p ≤ 0.001), and negatively with gray matter volume in the left inferior and middle frontal gyri. CONCLUSIONS Results suggest that a compulsivity spectrum exists in an adolescent, preclinical sample and accounts for variance in both OCD and ED, but not substance-related behaviors, and can be differentiated from an externalizing spectrum.
Collapse
Affiliation(s)
- Chantale Montigny
- Department of Psychiatry, Université de Montréal, CHU Ste Justine Hospital, Montreal, Canada
| | | | - Robert Whelan
- Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
- Departments of Psychiatry and Psychology, University of Vermont, Burlington, Vermont, United States of America
| | - Tobias Banaschewski
- Central Institute of Mental Health, Mannheim, Germany
- Mannheim Medical Faculty, University of Heidelberg, Germany
- Central Institute of Mental Health, Medical Faculty Mannheim / Heidelberg University, Department of Addictive Behaviour and Addiction Medicine, Manheim, Germany
| | | | | | - Jürgen Gallinat
- Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité, Universitätsmedizin Berlin, Germany
| | - Herta Flor
- Central Institute of Mental Health, Mannheim, Germany
- Mannheim Medical Faculty, University of Heidelberg, Germany
- Central Institute of Mental Health, Medical Faculty Mannheim / Heidelberg University, Department of Addictive Behaviour and Addiction Medicine, Manheim, Germany
| | - Karl Mann
- Central Institute of Mental Health, Mannheim, Germany
- Mannheim Medical Faculty, University of Heidelberg, Germany
- Central Institute of Mental Health, Medical Faculty Mannheim / Heidelberg University, Department of Addictive Behaviour and Addiction Medicine, Manheim, Germany
| | - Marie-Laure Paillère-Martinot
- Institut National de la Santé et de la Recherche Médicale, INSERM CEA Unit 1000 “Imaging & Psychiatry”, University Paris Sud, Orsay, France
- AP-HP Department of Adolescent Psychopathology and Medicine, Maison de Solenn, University Paris Descartes, Paris, France
| | - Frauke Nees
- Central Institute of Mental Health, Mannheim, Germany
- Mannheim Medical Faculty, University of Heidelberg, Germany
- Central Institute of Mental Health, Medical Faculty Mannheim / Heidelberg University, Department of Addictive Behaviour and Addiction Medicine, Manheim, Germany
| | | | - Eva Loth
- MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, London, United Kingdom
- Institute of Psychiatry, King’s College London, United Kingdom
| | - Tomas Paus
- Rotman Research Institute, University of Toronto, Toronto, Canada
- School of Psychology, University of Nottingham, United Kingdom
- Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Zdenka Pausova
- The Hospital for Sick Children, University of Toronto, Toronto, Canada
| | - Marcella Rietschel
- Central Institute of Mental Health, Mannheim, Germany
- Mannheim Medical Faculty, University of Heidelberg, Germany
- Central Institute of Mental Health, Medical Faculty Mannheim / Heidelberg University, Department of Addictive Behaviour and Addiction Medicine, Manheim, Germany
| | - Gunter Schumann
- MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, London, United Kingdom
- Institute of Psychiatry, King’s College London, United Kingdom
| | - Michael N. Smolka
- Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Germany
- Neuroimaging Center, Department of Psychology, Technische Universität Dresden, Germany
| | - Maren Struve
- Central Institute of Mental Health, Mannheim, Germany
| | - Trevor W. Robbins
- Behavioural and Clinical Neurosciences Institute, Department of Experimental Psychology, University of Cambridge, United Kingdom
| | - Hugh Garavan
- Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
- Departments of Psychiatry and Psychology, University of Vermont, Burlington, Vermont, United States of America
| | - Patricia J. Conrod
- Department of Psychiatry, Université de Montréal, CHU Ste Justine Hospital, Montreal, Canada
- Institute of Psychiatry, King’s College London, United Kingdom
| | | |
Collapse
|